Paulson Wealth Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.07M | Sell |
4,941
-187
| -4% | -$41.5K | 0.25% | 44 |
|
|
2025
Q4 | $1.17M | Sell |
5,128
-401
| -7% | -$91.3K | 0.27% | 41 |
|
|
2025
Q3 | $1.28M | Sell |
5,529
-355
| -6% | -$72.3K | 0.3% | 39 |
|
|
2025
Q2 | $1.09M | Sell |
5,884
-4
| -0.1% | -$743 | 0.28% | 39 |
|
|
2025
Q1 | $1.23M | Sell |
5,888
-200
| -3% | -$38.9K | 0.35% | 32 |
|
|
2024
Q4 | $1.08M | Sell |
6,088
-306
| -5% | -$56.3K | 0.3% | 38 |
|
|
2024
Q3 | $1.26M | Sell |
6,394
-700
| -10% | -$131K | 0.34% | 39 |
|
|
2024
Q2 | $1.22M | Sell |
7,094
-232
| -3% | -$38.4K | 0.36% | 40 |
|
|
2024
Q1 | $1.33M | Sell |
7,326
-72
| -1% | -$12.4K | 0.39% | 38 |
|
|
2023
Q4 | $1.15M | Sell |
7,398
-1,108
| -13% | -$162K | 0.37% | 39 |
|
|
2023
Q3 | $1.27M | Buy |
8,506
+944
| +12% | +$139K | 0.44% | 35 |
|
|
2023
Q2 | $1.02M | Buy |
7,562
+1,036
| +16% | +$152K | 0.35% | 42 |
|
|
2023
Q1 | $1.04M | Buy |
6,526
+107
| +2% | +$16.4K | 0.46% | 26 |
|
|
2022
Q4 | $1.04M | Sell |
6,419
-39
| -0.6% | -$5.98K | 0.51% | 25 |
|
|
2022
Q3 | $867K | Buy |
+6,458
| New | +$927K | 0.47% | 23 |
|
|
2021
Q4 | – | Sell |
-6,768
| Closed | -$730K | – | 89 |
|
|
2021
Q3 | $730K | Buy |
6,768
+14
| +0.2% | +$1.6K | 0.35% | 32 |
|
|
2021
Q2 | $761K | Buy |
6,754
+193
| +3% | +$21.7K | 0.37% | 30 |
|
|
2021
Q1 | $701K | Buy |
6,561
+137
| +2% | +$14.7K | 0.35% | 32 |
|
|
2020
Q4 | $688K | Buy |
6,424
+444
| +7% | +$42.7K | 0.4% | 32 |
|
|
2020
Q3 | $524K | Buy |
5,980
+437
| +8% | +$41.1K | 0.34% | 40 |
|
|
2020
Q2 | $544K | Buy |
5,543
+204
| +4% | +$18K | 0.38% | 37 |
|
|
2020
Q1 | $437K | Buy |
5,339
+301
| +6% | +$25.6K | 0.34% | 48 |
|
|
2019
Q4 | $443K | Buy |
5,038
+125
| +3% | +$10.4K | 0.31% | 61 |
|
|
2019
Q3 | $372K | Sell |
4,913
-173
| -3% | -$11.9K | 0.28% | 66 |
|
|
2019
Q2 | $344K | Buy |
5,086
+97
| +2% | +$7.62K | 0.26% | 76 |
|
|
2019
Q1 | $402K | Sell |
4,989
-85
| -2% | -$6.95K | 0.3% | 70 |
|
|
2018
Q4 | $450K | Sell |
5,074
-2,750
| -35% | -$242K | 0.37% | 64 |
|
|
2018
Q3 | $649K | Sell |
7,824
-339
| -4% | -$32.1K | 0.58% | 51 |
|
|
2018
Q2 | $756K | Sell |
8,163
-129
| -2% | -$12.6K | 0.75% | 41 |
|
|
2018
Q1 | $785K | Sell |
8,292
-937
| -10% | -$103K | 0.78% | 38 |
|
|
2017
Q4 | $893K | Buy |
+9,229
| New | +$870K | 0.78% | 36 |
|
Other funds holding ABBV
VCM
VPM
Paulson Wealth Management's ABBV Position: Q1 2026 in Review
Paulson Wealth Management reduced its AbbVie (ABBV) stake by 3.6% in Q1 2026, selling an estimated $41.5K and leaving 4,941 shares worth $1.07M. The position accounts for 0.25% of the portfolio, ranked #44.
Paulson Wealth Management first reported a position in ABBV in Q4 2017 and has held it in 31 quarters since. The position peaked at $1.33M in Q1 2024. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Paulson Wealth Management held 4,941 shares of AbbVie worth $1.07M as of Q1 2026.
- Paulson Wealth Management sold 187 AbbVie shares in Q1 2026, an estimated $41.5K.
- AbbVie made up 0.25% of Paulson Wealth Management's portfolio in Q1 2026, its #44 holding.
- Paulson Wealth Management first reported a position in AbbVie in Q4 2017 and has held it in 31 quarters since.
- Paulson Wealth Management's AbbVie position peaked at $1.33M in Q1 2024.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Paulson Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.